Spots Global Cancer Trial Database for chronic myeloid leukemia (cml)
Every month we try and update this database with for chronic myeloid leukemia (cml) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib | NCT02733445 | Chronic Myeloid... | dasatinib nilotinib | 18 Years - | Bristol-Myers Squibb | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans | NCT04126707 | Chronic Myeloid... | [14C] HQP1351 | 18 Years - 50 Years | Ascentage Pharma Group Inc. | |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality | NCT03746054 | Chronic Myeloid... | Optimal medical... usual clinical ... | 18 Years - | University Hospital, Angers | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Expanded Access Program of Ponatinib | NCT01592136 | Chronic Myeloid... Philadelphia Ch... | ponatinib | 18 Years - | Takeda | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population | NCT02363868 | Chronic Myeloid... | 18 Years - | Bristol-Myers Squibb | ||
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | NCT00433745 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1 Peptide Vac... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality | NCT03746054 | Chronic Myeloid... | Optimal medical... usual clinical ... | 18 Years - | University Hospital, Angers | |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | NCT02061800 | Chronic Myeloid... Acute Myelogeno... Myelodysplastic... Juvenile Myelom... Acute Lymphobla... Lymphoma (Hodgk... | CliniMACS CD34+... Thiotepa Cyclophosphamid... Alemtuzumab Tacrolimus Melphalan Busulfan Fludarabine Methylprednisol... | - 22 Years | Columbia University | |
| Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. | NCT01605981 | Chronic Myeloid... | AMN107 | 18 Years - | Novartis | |
| Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. | NCT01605981 | Chronic Myeloid... | AMN107 | 18 Years - | Novartis | |
| Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population | NCT02363868 | Chronic Myeloid... | 18 Years - | Bristol-Myers Squibb | ||
| Expanded Access Program of Ponatinib | NCT01592136 | Chronic Myeloid... Philadelphia Ch... | ponatinib | 18 Years - | Takeda | |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | NCT02790515 | Acute Lymphobla... Acute Myeloid L... Myeloid Sarcoma Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Non-Hodgkin Lym... | Anti-thymocyte ... Blinatumomab Cyclophosphamid... Fludarabine G-CSF Melphalan Mesna Rituximab Tacrolimus Thiotepa HPC,A Infusion CliniMACS Sirolimus | - 21 Years | St. Jude Children's Research Hospital | |
| Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population | NCT02363868 | Chronic Myeloid... | 18 Years - | Bristol-Myers Squibb | ||
| EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors | NCT03481868 | Chronic Myeloid... Chronic Phase | Collection of b... | 18 Years - | University Hospital, Clermont-Ferrand | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
